Hengrui Pharmaceutical (01276): SHR-9539 injection and HRS-3738 tablets received drug clinical trial approval notice

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-9539 injections and HRS-3738 tablets, which will conduct clinical trials in the near future.

SHR-9539 injection is a class 1 therapeutic biological product. By recruiting and activating T cells, it can target and kill multiple myeloma cells. Currently, no similar drugs have been approved for marketing in China. Up to now, the total R&D investment for SHR-9539 injection-related projects is about 39.93 million yuan.

HRS-3738 tablets are a new generation of high-efficiency CRBNE3 ubiquitin ligase modulators. It affects the proliferation of hematoma cells by degrading specific substrates, has strong ability to degrade substrates, and has the potential advantage of overcoming drug resistance. According to inquiries, no similar drugs have been approved for marketing at home or abroad. Up to now, HRS-3738 film-related projects have invested a total of about 63.63 million yuan in R&D.